PROTAC ER Degrader-3

PROTAC ER Degrader-3

• CAS Number: 2158322-29-1
• UNSPSC Description: PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab)[1].
• Target Antigen: Estrogen Receptor/ERR; PROTACs
• Type: Reference compound
• Related Pathways: PROTAC;Vitamin D Related/Nuclear Receptor
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/protac-er-degrader-3.html
• Solubility: 10 mM in DMSO
• Smiles: OC1=CC=C(/C(C2=CC=C(OCCN(C)C(COCCOCCNC(C3=CC=C(C(N4[C@@H](C)[C@H](NC([C@H](C)N(C(OC(C)(C)C)=O)C)=O)C(N(CC5=C(OC)C=CC6=C5C=CC=C6)C7=C4C=C(C#N)C=C7)=O)=O)C=C3)=O)=O)C=C2)=C(CC)/C8=CC=CC=C8)C=C1
• Molecular Weight: 1220.41
• References & Citations: [1]Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported